The Celebrex data

Although congressional critics immediately jumped on Friday's news of adverse cardiovascular events among users of Celebrex celecoxib, in fact Pfizer Inc. reported contradictory safety results from two long-term trials of the COX-2 inhibitor.

In the five-year, NCI-sponsored APC (Adenoma Prevention with Celecoxib) trial, 3% of

Read the full 443 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE